These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30231761)

  • 1. Pragmatic Multicriteria Decision Analysis (MCDA) Combined With Advanced Pharmacoepidemiology for Benefit-Risk Assessments of Medicines Adapted to the Real-Life Constraints of Regulators: Development and Case Study.
    Goetghebeur MM; Wagner M; Nikodem M; Zyla A; Micaleff A; Amzal B
    Ther Innov Regul Sci; 2016 Sep; 50(5):620-631. PubMed ID: 30231761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient-Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context.
    Wagner M; Samaha D; Cuervo J; Patel H; Martinez M; O'Neil WM; Jimenez-Fonseca P
    Adv Ther; 2018 Aug; 35(8):1215-1231. PubMed ID: 29987525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.
    Goetghebeur MM; Wagner M; Khoury H; Rindress D; Grégoire JP; Deal C
    Cost Eff Resour Alloc; 2010 Apr; 8():4. PubMed ID: 20377888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
    Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
    BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.
    Miot J; Wagner M; Khoury H; Rindress D; Goetghebeur MM
    Cost Eff Resour Alloc; 2012 Feb; 10(1):2. PubMed ID: 22376143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple way to unify multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) using a Dirichlet distribution in benefit-risk assessment.
    Saint-Hilary G; Cadour S; Robert V; Gasparini M
    Biom J; 2017 May; 59(3):567-578. PubMed ID: 28187230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology.
    Badia X; Aguarón A; Fernández A; Gimón A; Nafria B; Gaspar B; Guarga L; Gálvez M; Fuentes M; Paco N; Saldaña R
    Int J Technol Assess Health Care; 2019 Jan; 35(1):56-63. PubMed ID: 30730288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
    Jiménez A; Ais A; Beaudet A; Gil A
    Orphanet J Rare Dis; 2018 Dec; 13(1):220. PubMed ID: 30526673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
    Villanueva V; Carreño M; Gil-Nagel A; Serrano-Castro PJ; Serratosa JM; Toledo M; Álvarez-Barón E; Gil A; Subías-Labazuy S
    Epilepsy Behav; 2021 Sep; 122():108222. PubMed ID: 34371462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting.
    Hoshikawa K; Ono S
    J Clin Pharm Ther; 2017 Feb; 42(1):80-86. PubMed ID: 27914099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two approaches to incorporate clinical data uncertainty into multiple criteria decision analysis for benefit-risk assessment of medicinal products.
    Wen S; Zhang L; Yang B
    Value Health; 2014 Jul; 17(5):619-28. PubMed ID: 25128056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).
    Guarga L; Badia X; Obach M; Fontanet M; Prat A; Vallano A; Torrent J; Pontes C
    Orphanet J Rare Dis; 2019 Jun; 14(1):157. PubMed ID: 31248421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain).
    Gasol M; Paco N; Guarga L; Bosch JÀ; Pontes C; Obach M
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Application of Multicriteria Decision Analysis Methods in Health Care: A Literature Review.
    Khan I; Pintelon L; Martin H
    Med Decis Making; 2022 Feb; 42(2):262-274. PubMed ID: 34166149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study.
    Wahlster P; Goetghebeur M; Schaller S; Kriza C; Kolominsky-Rabas P;
    Health Res Policy Syst; 2015 Apr; 13():24. PubMed ID: 25928535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).
    Garau M; Hampson G; Devlin N; Mazzanti NA; Profico A
    Pharmacoecon Open; 2018 Jun; 2(2):153-163. PubMed ID: 29623625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory requirements and optimization of multiple criteria decision analysis to quantify the benefit-risk assessment of medical devices.
    Su G; Deng D
    Expert Rev Med Devices; 2023 Apr; 20(4):273-281. PubMed ID: 36896851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicriteria decision analysis in health care decision in oncology: a systematic review.
    Campolina AG; Suzumura EA; Hong QN; de Soárez PC
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):365-380. PubMed ID: 34913775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.